Experimental and Therapeutic Medicine Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP1, GIP, and Glucagon Agonists Khan 2026 Journal of Peptide Science Wiley Online Library Medicating Appetite: What Ozempic, Wegovy, and Other GLP 1 Drugs Really Mean